Simultaneous determination of niacin and its metabolites - Nicotinamide, nicotinuric acid and N-methyl-2-pyridone-5-carboxamide - In human plasma by LC-MS/MS and its application to a human pharmacokinetic study

Biomedical Chromatography

Volumn 24, Issue 10, 2010, Pages 1059-1074

  Inamadugu, Jaswanth Kumar ^a,b   Damaramadugu, Rajasekhar ^a,b   Mullangi, Ramesh ^c   Ponneri, Venkateswarlu ^a  

^a SRI VENKATESWARA UNIVERSITY   (India)

^b Wellquest Clinical Research Laboratories   (India)

^c Jubilant Innovation   (India)

Author keywords

Human plasma; LC MS MS; Method validation; N methyl 2 pyridone 5 carboxamide; Niacin; Nicotinamide; Nicotinuric acid; Pharmacokinetics

Indexed keywords

AMIDES; BIOMOLECULES; CARBOXYLIC ACIDS; LIQUID CHROMATOGRAPHY; METABOLITES; PLASMA (HUMAN); PYRIDINE; SOLVENT EXTRACTION;

2-PYRIDONES; CARBOXAMIDES; HUMAN PLASMAS; LC-MS-MS; LC.MS/MS; METHOD VALIDATIONS; N-METHYL-2-PYRIDONE-5-CARBOXAMIDE; NIACIN; NICOTINAMIDE; NICOTINURIC ACID;

PHARMACOKINETICS;

ACETONITRILE; DRUG METABOLITE; FORMIC ACID; N METHYL 2 PYRIDONE 5 CARBOXAMIDE; NEVIRAPINE; NICOTINAMIDE; NICOTINIC ACID; NICOTINURIC ACID; UNCLASSIFIED DRUG;

ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ISOLATION; ELUTION; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; QUANTITATIVE ASSAY; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

EID: 77957296111     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1406     Document Type: Article

References (31)

1. Altschul R, Hoffer A and Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Archives of Biochemistry 1955; 54: 558-559.
2. Becker B and Hummel K. A new method for determination of nicotinic acid in plasma. Arzneimittelforschung 1990; 40: 573-575.
3. Benyo Z, Gille A, Kero J, Csiky M, Suchánková MC, Nüsing RM, Moers A, Pfeffer K and Offermanns S. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. Journal of Clinical Investigation 2005; 115: 3634-3640.
4. Brown MS and Goldstein ML. Drugs Used in the Treatment of Hyperlipoproteinemias, 8th edn. Pergamon Press: New York, 1990.
5. Carlson LA, Oro L and Ostman J. Effect of single dose of nicotinic acid on plasma lipids in patients with hyperlipoproteinemia. Acta Medica Scandinavica 1968; 183: 457-465.
6. Catz P, Shinn W, Kapetanovic IM, Kim H, Kim M, Jacobson EL, Jacobson MK and Green CE. Simultaneous determination of myristyl nicotinate, nicotinic acid, and nicotinamide in rabbit plasma by liquid chromatography- tandem mass spectrometry using methyl ethyl ketone as a deproteinization solvent. Journal of Chromatography B 2005; 829: 125-135.
7. de Vires JX, Gunthert W and Ding J. Determination of nicotinamide in human plasma and urine by ion-pair reversed-phase high-performance liquid chromatography. Journal of Chromatography 1980; 221: 161-165.
8. Dams R, Huestis MA, Lambert WE and Murphy CM. Matrix effect in bioanalysis of illicit drugs with LC-MS/MS: influence of ionization type, sample preparation, and biofluid. Journal of American Society for Mass Spectrometry 2003; 14: 1290-1294.
9. Grundy SM, Mok HY, Zech L and Berman M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. Journal of Lipid Research 1981; 22: 24-36.
10. Hengen N, Seiberth V and Hengen M. High-performance liquid- chromatographic determination of free nicotinic acid and its metabolite, nicotinuric acid, in plasma and urine. Clinical Chemistry 1978; 24: 1740-1743.
11. Hubert Ph, Chiap P, Crommen J, Boulanger B, Chapuzet E, Mercier N, Bervoas-Martin S, Chevalier P, Grandjean D, Lagorce P, Lallier M, Laparra MC, Laurentie M and Nivet JC. The SFSTP guide on the validation of chromatographic methods for drug bioanalysis Washington conférence to the laboratory. Analytica Chimica Acta 1999; 391: 135-148.
12. Li AC, Chen YL, Junga H, Shou WZ, Jiang X and Naidong W. Separation of nicotinic acid and six metabolites within 60 sec using high-flow gradient chromatography on silica column with tandem mass spectrometric detection. Chromatographia 2003; 58: 723-731.
13. Mallett DN, Dayal S, Dear GJ and Pateman AJ. The determination of nicotinic acid in plasma by mixed-mobile liquid chromatography-tandem mass spectrometry following ion exchange solid phase extraction. Journal of Pharmaceutical and Biomedical Analysis 2006; 41: 510-516.
14. Menon RM, Gonzalez MA, Adams MH, Tolbet DS, Leu JH and Cefali EA. Effect of the rate of niacin administration on the plasma and urine pharmacokinetics of niacin and its metabolites. Journal of Clinical Pharmacology 2007a; 47: 681-688.
15. Menon RM, Adams MH, Gonzalez MA, Tolbet DS, Leu JH and Cefali EA. Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. International Journal of Clinical Pharmacology and Therapeutics 2007b; 45: 448-454.
16. Miyauchi Y, Sano N and Nakamura T. Simultaneous determination of nicotinic acid and its two metabolites in human plasma using solid-phase extraction in combination with high performance liquid chromatography. International Journal of Vitamin Nutrition Research 1993; 63: 145-149.
17. Musfeld C, Biollaz J, Belaz N, Kesslring UW and Decosterd LA. Validation of an HPLC method for the determination of urinary and plasma levels of N1-methyl-nicotinamide, an endogenous marker of renal cationic transport and plasma flow. Journal of Pharmaceutical and Biomedical Analysis 2001; 24: 391-404.
18. Papadoyannis IN, Tsioni GK and Smanidon VF. Simultaneous determination of nine water and fat soluble vitamins after SPE separation and RP-HPLC analysis of pharmaceutical preparations and biological fluids. Journal of Chromatography and Related Technologies 1997; 20: 3203-3231.
19. Pelzer M, Northcott S and Hanson G. An improved method for the determination of nicotinic acid in human plasma by high-performance liquid chromatography. Journal of Chromatography and Related Technologies 1993; 16: 2563-2570.
20. Peoples MC, Halquist MS, Ismaiel O, El-Mammli MY, Shalaby A and Karnes HT. Assessment of matrix effects and determination of niacin in human plasma using liquid-liquid extraction and liquid chromatography- tandem mass spectrometry. Biomedical Chromatography 2008; 22: 1271-1278.
21. Pfuhl P, Karcher U, Haring N, Baumeister A, Tawab MA and Schubert- Zsilavecz M. Simultaneous detemination of niacin, niacinamide and nicotinuric acid in human plasma. Journal Pharmaceutical and Biomedical Analysis 2005; 36: 1045-1052.
22. Pieper JA. Understanding niacin formulations. The American Journal of Managed Care 2002; 8: S308-S314.
23. Piepho RW. The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. American Journal of Cardiology 2000; 86: 35L-40L.
24. Pieper JA. Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety. American Journal of Health-System Pharmacy 2003; 60: S9-14.
25. 1-methyl-2- pyridone-5-carboxamide, a major metabolite of nicotinic acid and nicotinamide, in urine by high-performance liquid chromatography. Journal of Chromatography 1987; 417: 173-177.
26. Stern RH. The role of nicotinic acid metabolites in flushing and hepatotoxicity. Journal of Clinical Lipidology 2007; 1: 191-193.
27. Stratford MR and Dennis MF. High-performance liquid chromatographic determination of nicotinamide and its metabolites in human and murine plasma and urine. Journal of Chromatography 1992; 582: 145-151.
28. Takikawa K, Miyazaki K and Arita T. High-performance liquid chromatographic determination of nicotinic acid and its metabolites, nicotinuric acid and nicotinamide, in plasma. Journal of Chromatography 1982; 233: 343-348.
29. Tsuruta T, Kohashi K, Ishida S and Ohkura Y. Determination of nicotinic acid in serum by high-performance liquid chromatography with fluorescence detection. Journal of Chromatography 1984; 309: 309-315. (Pubitemid 14061679)
30. US DHHS, FDA, CDER. Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine, 2001. Available from: http://www/fda.gov/cder/ guidance/index.htm
31. US DHHS, FDA, CDER. Guidance for Industry: Bioequivalence Guidance. US Department of Health and Human Services, Food and Drug Administration, Center for Veterinary Medicine, 2006. Available from: http:// www/fda.gov/cder/ guidance/index.htm